MedRhythms has initiated its partnership with EVERSANA, a provider of global commercialization services to the life sciences industry, to launch and commercialize MR-001, its patented software-based medical device designed to treat chronic stroke walking deficits.
The product received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) in June 2020.
To support its anticipated launch, MedRhythms will utilize EVERSANA’s fully integrated commercialization services that include market access, agency services, clinical and commercial field teams, medical science liaisons, channel management, patient services, health economics and outcomes research, and compliance, with each service optimized by data and predictive analytics, the company notes in a media release.
“Today’s announcement marks a significant milestone in our commitment to serve chronic stroke survivors who have waited lifetimes for a standard of care. After years of development and testing, we stand ready to successfully launch this groundbreaking innovation with a best-in-class commercialization partner.”
— Owen McCarthy, President and Co-founder of MedRhythms
“This breakthrough device demands a breakthrough, transformative approach to launch and commercialization. We’re ready to deploy the full power of our infrastructure and experts to navigate the complexities of digital therapy launches to ensure this innovation quickly reaches the millions of chronic stroke patients desperately in need of treatment and a better quality of life.”
— Jim Lang, Chief Executive Officer of EVERSANA
[Source(s): MedRhythms, PR Newswire]
Related Content:
MedRhythms Chronic Stroke Digital Therapeutic Receives FDA Breakthrough Designation
